Latest Product Development News

Aguia Resources has secured key contracts and financing steps for its Tres Estradas phosphate project in Brazil, aiming for production start by late 2025 and first sales in early 2026.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Nanoveu Limited has completed the first tranche of a $2.7 million capital raise, issuing over 61 million shares to bolster its advanced semiconductor and materials science ventures. Additional placements to executives and the Chairman are planned, pending shareholder approval.

Yowie Group has announced an all-scrip off-market takeover bid for Keybridge Capital, offering one Yowie share per Keybridge share. The bid is subject to key regulatory and shareholder approvals, setting the stage for a significant consolidation in the ASX-listed consumer goods and investment sectors.

Wide Open Agriculture secures $2.6 million via placement and plans a $500,000 Share Purchase Plan to fast-track its expansion into China and boost global sales of its lupin protein products.

Swift Networks Group has successfully raised $2.3 million through a 71% subscribed entitlement offer, restructuring its loan facility to support the rollout of its next-generation Swift Access 2025 platform.

Generation Development Group (GDG) has forged a strategic alliance with BlackRock, combining local market leadership with global investment expertise to develop innovative retirement income solutions for Australian retirees.

Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.

MyEco Group has secured $1.6 million through unsecured convertible notes to support a strategic operational restructure aimed at reducing costs and scaling production. This capital raise complements existing cash reserves and aims to improve margins while minimising shareholder dilution.

Enlitic Inc. has been reinstated to trading on the ASX following its announcement of a new equity raise, signaling renewed investor interest in the health technology firm.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.